Biogen Aktie

163,85 EUR -1,30 EUR -0,79 %

16:18:29

STU

194,13 USD -1,28 USD -0,66 %

16:23:37

BTT

Biogen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.24,37 Mrd. EUR

KGV20,02Div. Rendite0,00%

WKN789617

ISINUS09062X1037

SymbolBIIB

Biogen Aktien News

Sortieren:Datum Meistgelesen

14.12.23GlobeNewswireZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

06.11.23GlobeNewswireBiogen Appoints Monish Patolawala to its Board of Directors

25.10.23GlobeNewswireEisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional

25.10.23PR NewswireEISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITI...

25.10.23GlobeNewswireNew Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

24.10.23PR NewswireLEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023

19.10.23GlobeNewswireBiogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

29.09.23GlobeNewswireFDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

26.09.23GlobeNewswireBiogen Completes Acquisition of Reata Pharmaceuticals

25.09.23GlobeNewswireLEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

06.09.23GlobeNewswireBiogen Appoints Jane Grogan as Head of Research

05.08.23GlobeNewswireFDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

28.07.23GlobeNewswireBiogen to Acquire Reata Pharmaceuticals

20.07.23GlobeNewswireEisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023

07.07.23PR NewswireFDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

07.07.23GlobeNewswireFDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

30.06.23GlobeNewswireNew Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

12.06.23GlobeNewswireBiogen Announces Changes to Its Board of Directors

10.06.23PR NewswireFDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

10.06.23GlobeNewswireFDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

16.05.23GlobeNewswireHealth Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

25.04.23GlobeNewswireFDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

31.03.23PR NewswireADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS

31.03.23PR NewswireEISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING

31.03.23GlobeNewswireEisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

31.03.23GlobeNewswireAdditional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

29.03.23GlobeNewswireNew Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

23.03.23GlobeNewswireBiogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

16.03.23GlobeNewswireBiogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

08.03.23GlobeNewswireCaroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

06.03.23PR NewswireFDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

06.03.23GlobeNewswireFDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

28.02.23PR NewswireBIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

28.02.23GlobeNewswireBiologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

Biogen News

Biogen News: auf dieser Seite finden Sie alle Biogen News und Nachrichten zur Biogen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biogen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biogen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.